| Prev Close | 3.39 |
| Day Low/High | 3.44 / 3.66 |
| 52 Wk Low/High | 3.10 / 23.04 |
bluebird bio, Inc. (BLUE)
3.62
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 71.45B |
| Market Cap | 242.23M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Movers Before the Market Opened
Premarket movers: Upside - +157% (reports two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture) - +13% (The Phoenix Holdings Ltd. discloses 11.60% stake; appoints Josh Tech as Chief Operations Officer, effec...
Top Stock Picks for 2022 in Biotech and Genetics
Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.
The Suppressed Economy, Impressive Earnings, U.S. Treasury Curve, Pandemic Watch
I want you to think about how quickly the long end of the U.S. Treasury curve is moving.
Bluebird Bio Is Not Ready to Fly
BLUE needs a bigger base to launch a sustained uptrend.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing
Charts are pointing the way to an upside recovery for this stock.
Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries
Diplomacy must precede presidential threats.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
Which Hot Biotech Name Will Be Acquired Next?
Your burning biotech questions answered in our latest mailbag.
Bret Jensen's Biotech Mailbag
We'll answer two of the common questions we have received so far in March.
2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Circle These Biotech Acquisition Candidates
Outside of oncology, the rare disease area is a good target for M&A in 2018.
How Trading Notes Can Increase Your Profits
Inertia is your biggest enemy in this market.
Video: Jim Cramer on Bitcoin, Bluebird Bio and This Weeks Fed Meeting
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending topics including bitcoin futures, Bluebird Bio and what to expect from this week's Federal Reserve meeting.
Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored
There are some signs of selling into the strength especially in technology names.
Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks
This team is playoff-ready and built for the ages.
Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor
I've cut a few positions and haven't made any notable buys today.
Cramer: There Should Be More Takeovers Where These Came From
Buying's good for the acquirers, which should give other companies ideas.
Kite Takeover by Gilead Lifts Biotech Stocks
The key to dealing with this environment is to keep an open mind.
Time to Take Profits in Bluebird Bio
This biotech has done well so far this year, but now it's time to lock in some gains.
Bluebird Bio Looks Set to Soar Upward
Meal worms not needed to give it strength.
Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success
Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.
Why Celgene Is a Core Biotech Holding
Celgene's days of stellar growth will continue to stretch far into the future.
Trader's Daily Notebook: You Might Consider Selling Facebook
Do that if you like top ticking crowd favorites, but set a protective stop.
